Name: Bavdegalutamide

Cat#:EX-A5017

Structure



Chemical Name	N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3-carboxamide

Molecular Weight	812.29	Storage	2 years -20°C powder 6 months -80°C in solvent Away from light
Formula	C41H43ClFN9O6		
CAS No.	2222112-77-6	Synonyms	ARV-110

Solubility (25°C) *	In vitro	DMSO	26.67 mg/mL (32.83 mM; ultrasonic and warming and adjust pH to 3 with HCl and heat to 80°C)
		Ethanol	Insoluble
		Water	Insoluble
	In vivo （should be freshly prepared each time）		

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions:

Mass / Volume / Concentration	1 mg	5 mg	10 mg

1 mM	1.2311 mL	6.1554 mL	12.3109 mL
5 mM	0.2462 mL	1.2311 mL	2.4622 mL
10 mM	0.1231mL	0.6155 mL	1.2311 mL
50 mM	0.0246 mL	0.1231 mL	0.2462 mL

Biological Activities:

Description	ARV-110 is an orally bioavailable, specific androgen receptor (AR) PROTAC degrader that leads to ubiquitination and degradation of AR. ARV-110 completely degrades androgen receptor (AR) in all cell lines tested with DC50 of < 1 nM. ARV-110 can be used for the research of prostate cancer.

Targets	AR[1] (Cell-free assay)
	1 nM(DC50)
In vitro	Bavdegalutamide completely degrades AR in all cell lines tested, with an observed 50% degradation concentration (DC50) <1 nM[1] .Bavdegalutamide (0.01 nM-300 nM) leads to AR degradation in LNCaP cells in a dose-dependent manner[1].
In vivo	
References	[1] Taavi Neklesa, et al. Cancer Res 2018;78(13 Suppl):Abstract nr 5236.